Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/55b42be9041b432a9d2261b9a37780c0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55b42be9041b432a9d2261b9a37780c0
record_format	dspace
spelling	oai:doaj.org-article:55b42be9041b432a9d2261b9a37780c02021-12-02T03:50:06ZEffect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor1179-1438https://doaj.org/article/55b42be9041b432a9d2261b9a37780c02013-04-01T00:00:00Zhttp://www.dovepress.com/effect-of-famotidine-on-the-pharmacokinetics-of-apixaban-an-oral-direc-a12774https://doaj.org/toc/1179-1438Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, 3Primary Care Clinical Pharmacology, Pfizer, Groton, CT, 4Analytical and Bioanalytical Department, Bristol-Myers Squibb, Princeton, NJ, USA Background: Apixaban is an oral, selective, direct factor Xa inhibitor approved for thromboprophylaxis after orthopedic surgery and stroke prevention in patients with atrial fibrillation, and under development for treatment of venous thromboembolism. This study investigated the effect of a gastric acid suppressant, famotidine (a histamine H2-receptor antagonist), on the pharmacokinetics of apixaban in healthy subjects. Methods: This two-period, two-treatment crossover study randomized 18 healthy subjects to receive a single oral dose of apixaban 10 mg with and without a single oral dose of famotidine 40 mg administered 3 hours before dosing with apixaban. Plasma apixaban concentrations were measured up to 60 hours post-dose and pharmacokinetic parameters were calculated. Results: Famotidine did not affect maximum apixaban plasma concentration (Cmax) or area under the plasma concentration-time curve from zero to infinite time (AUC∞). Point estimates for ratios of geometric means with and without famotidine were close to unity for Cmax (0.978) and AUC∞ (1.007), and 90% confidence intervals were entirely contained within the 80%–125% no-effect interval. Administration of apixaban alone and with famotidine was well tolerated. Conclusion: Famotidine does not affect the pharmacokinetics of apixaban, consistent with the physicochemical properties of apixaban (lack of an ionizable group and pH-independent solubility). Apixaban pharmacokinetics would not be affected by an increase in gastrointestinal pH due to underlying conditions (eg, achlorhydria), or by gastrointestinal pH-mediated effects of other histamine H2-receptor antagonists, antacids, or proton pump inhibitors. Given that famotidine is also an inhibitor of the human organic cation transporter (hOCT), these results indicate that apixaban pharmacokinetics are not influenced by hOCT uptake transporter inhibitors. Overall, these results support that apixaban can be administered without regard to coadministration of gastric acid modifiers. Keywords: apixaban, factor Xa inhibitor, famotidine, H2-receptor antagonists, hOCT inhibitor, drug–drug interactionUpreti VVSong YWang JByon WBoyd RAPursley JMLaCreta FFrost CEDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Issue 1, Pp 59-66 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Upreti VV Song Y Wang J Byon W Boyd RA Pursley JM LaCreta F Frost CE Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
description	Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, 3Primary Care Clinical Pharmacology, Pfizer, Groton, CT, 4Analytical and Bioanalytical Department, Bristol-Myers Squibb, Princeton, NJ, USA Background: Apixaban is an oral, selective, direct factor Xa inhibitor approved for thromboprophylaxis after orthopedic surgery and stroke prevention in patients with atrial fibrillation, and under development for treatment of venous thromboembolism. This study investigated the effect of a gastric acid suppressant, famotidine (a histamine H2-receptor antagonist), on the pharmacokinetics of apixaban in healthy subjects. Methods: This two-period, two-treatment crossover study randomized 18 healthy subjects to receive a single oral dose of apixaban 10 mg with and without a single oral dose of famotidine 40 mg administered 3 hours before dosing with apixaban. Plasma apixaban concentrations were measured up to 60 hours post-dose and pharmacokinetic parameters were calculated. Results: Famotidine did not affect maximum apixaban plasma concentration (Cmax) or area under the plasma concentration-time curve from zero to infinite time (AUC∞). Point estimates for ratios of geometric means with and without famotidine were close to unity for Cmax (0.978) and AUC∞ (1.007), and 90% confidence intervals were entirely contained within the 80%–125% no-effect interval. Administration of apixaban alone and with famotidine was well tolerated. Conclusion: Famotidine does not affect the pharmacokinetics of apixaban, consistent with the physicochemical properties of apixaban (lack of an ionizable group and pH-independent solubility). Apixaban pharmacokinetics would not be affected by an increase in gastrointestinal pH due to underlying conditions (eg, achlorhydria), or by gastrointestinal pH-mediated effects of other histamine H2-receptor antagonists, antacids, or proton pump inhibitors. Given that famotidine is also an inhibitor of the human organic cation transporter (hOCT), these results indicate that apixaban pharmacokinetics are not influenced by hOCT uptake transporter inhibitors. Overall, these results support that apixaban can be administered without regard to coadministration of gastric acid modifiers. Keywords: apixaban, factor Xa inhibitor, famotidine, H2-receptor antagonists, hOCT inhibitor, drug–drug interaction
format	article
author	Upreti VV Song Y Wang J Byon W Boyd RA Pursley JM LaCreta F Frost CE
author_facet	Upreti VV Song Y Wang J Byon W Boyd RA Pursley JM LaCreta F Frost CE
author_sort	Upreti VV
title	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
title_short	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
title_full	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
title_fullStr	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
title_full_unstemmed	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
title_sort	effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor xa inhibitor
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/55b42be9041b432a9d2261b9a37780c0
work_keys_str_mv	AT upretivv effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT songy effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT wangj effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT byonw effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT boydra effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT pursleyjm effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT lacretaf effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor AT frostce effectoffamotidineonthepharmacokineticsofapixabananoraldirectfactorxainhibitor
_version_	1718401600173637632

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Ejemplares similares